This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

2 Nov 2011

Alnylam & GSK Form Collaboration on RNAi Technology

Alnylam Pharmaceuticals announced Tuesday its collaboration with GSK focused on Alnylam's VaxiRNA technology for certain GSK vaccine products.

RNAi therapeutics company Alnylam Pharmaceuticals, Inc. announced Tuesday its collaboration with GlaxoSmithKline focused on Alnylam's VaxiRNA technology for certain GSK vaccine products, including influenza.


VaxiRNA is a new RNAi technology for the enhanced production of viruses used in the manufacture of vaccine products. GSK, a leading vaccine manufacturer, is the first company to form a collaboration accessing this new platform.


The GSK collaboration is focused initially on influenza vaccine production in cell culture systems. Under the terms of the agreement, GSK will provide funding and certain milestone payments to Alnylam. If successfully applied in the manufacture of commercial product, Alnylam will receive payments on unit product s

Related News